3,4-methylenedioxyphenylimidazolylethanonexime ether derivative, preparation method and use thereof, and drug for the treatment of Alzheimer's disease
US11680062B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 14, 2022 |
| Grant date | Jun 20, 2023 |
| Priority date | — |
| Expiry date | Feb 14, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/28
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Disclosed are 3,4-methylenedioxyphenylimidazolylethanonexime ether derivatives, a preparation method and use thereof, and a drug for the treatment of Alzheimer's disease, which relates to the technical field of preparation of acetophenone oxime ether compounds. The (Z)-3,4-methylenedioxyphenylimidazolylethanonexime ether derivatives provided by the present disclosure show a significant effect on the inhibition of NO production, with an EC50 of 2.07-5.41 μmol/L. Compared with the positive control group of quercetin (with an EC50 of 9.56 μmol/L) and oxiconazole (with an EC50 of 13.5 μmol/L), the inhibitory effect is stronger without significant cytotoxicity (cell viability >90%), which can be used to prepare drugs for the treatment of Alzheimer's disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.